Klin Farmakol Farm. 2011;25(4):193-198

A side effect of calcium channel blockers - ankle oedema. A case report.

Milan Grundmann, Ivana Kacířová
Ústav klinické farmakologie Ostrava
Lékařská fakulta Ostravské univerzity a Fakultní nemocnice Ostrava

Introduction: Arterial hypertension is present in 60% to 80% of renal transplant recipients. Angiotenzin-converting enzyme inhibitors

(ACEIs) are safe and effective and in combination with calcium channel blockers (CCBs) control arterial pressure more adequately than

either class alone. Ankle oedema is a common adverse event of CCBs and is responsible for treatment discontinuation or limited patient

compliance with antihypertensive treatment and has a deleterious impact on health-related quality of life.

Method: A patient after renal transplantation was treated with cyclosporine A and mycophenolate and a combination of five antihypertensive

drugs including amlodipine. The patient suffered from marked bilateral ankle oedema but his hypertension was well controlled.

The dose of amlodipine was decreased from 10 mg/day to 5 mg/day and later to 2.5 mg/day and the dose of perindopril was increased

from 5 mg/day to 10 mg/day. We followed up the casual blood pressure, ABPM and home blood pressure during one year. The aim was

to eliminate ankle oedema, increase the quality of life and control blood pressure.

Results: Ankle oedema started to diminish after three weeks and disappeared during the treatment with a dose of amlodipine of 2.5 mg/

day and that of perindopril of 10 mg/day. The patient was able to use normal shoes and his mobility and sexual activity were significantly

improved. His blood pressure remained well controlled in all methods of measurement and changes in the doses of both antihypertensive

drugs prevented fluctuation of systolic blood pressure and pulse rate during the day.

Conclusion: The marked ankle oedema due to amlodipine was eliminated by reducing the dose of the calcium channel blocker and

increasing the dose of the ACEI perindopril while maintaining normotension. The fluctuations of systolic blood pressure and pulse rate

were also diminished.

Keywords: renal transplantation, hypertension, calcium channel blockers, oedema, quality of life

Published: December 18, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Grundmann M, Kacířová I. A side effect of calcium channel blockers - ankle oedema. A case report. Klin Farmakol Farm. 2011;25(4):193-198.
Download citation

References

  1. Fernandez-Vega F, Tejada F, Baltar J, et al. Ambulatory blood pressure after renal transplantation. Nephrol Dial Transplant 2001; 16(Suppl 1): 110-113. Go to original source... Go to PubMed...
  2. Goldsmith DJA, Covic A, Venning MC, Ackrill P. Ambulatory blood pressure monitoring in renal dialysis and transplant patients. Am J Kidney Dis 1997; 29: 593. Go to original source... Go to PubMed...
  3. Lipkin GW, Tucker B, Giles M, Raine AEG. Ambulatory blood pressure and left ventricular mass in cyclosporin and non-cyclosporin-treated renal transplant recipients. J Hypertens 1993; 11: 439. Go to original source... Go to PubMed...
  4. McGregor DO, Olsson C, Lynn KL. Autonomic dysfunction and ambulatory blood pressure in renal transplant recipients. Transplantation 2001; 71(9): 1277-1281. Go to original source... Go to PubMed...
  5. Huysmans FT, Hoitsma AJ, Koene RA. Factors determining the prevalence of hypertension after renal transplantation. Nephrol Dial Transplant 1987; 2: 34-38.
  6. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure: Collaborative Transplant Study. Kidney Int 1998; 53: 217-222. Go to original source... Go to PubMed...
  7. Cosio FG, Pelletier RP, Pesavento TE, et al. Elevated blood pressure predicts the risk of acute rejection in renal allograft recipients. Kidney Int 2001; 59: 1158-1164. Go to original source... Go to PubMed...
  8. Gatzka CD, Schobel HP, Klingbeil AU, et al. Normalization of circadian blood pressure profiles after renal transplantation. Transplantation 1995; 59(9): 1270-1274. Go to original source... Go to PubMed...
  9. Lingens N, Dobos E, Lemmer B, et al. Nocturnal blood pressure elevation in transplanted pediatric patients. Kidney Int 1996; 49(Suppl 55): 175-176.
  10. Covic A, Segall L, Goldsmith DJA. Ambulatory blood pressure monitoring in renal transplantation: should ABPM be routinely performed in renal transplant patients? Transplantation 2003; 76(11): 1640-1642. Go to original source... Go to PubMed...
  11. Cifkova R, Hallen H. Cyclosporin-induced hypertension. J Hypertens 2001; 19(12): 2283-2285. Go to original source... Go to PubMed...
  12. van den Dorpel MA, van den Meiracker AH, Lameris TW, et al. Cyclosporin A impairs the nocturnal blood pressure fall in renal transplant recipients. Hypertension 1996; 28: 304-307. Go to original source... Go to PubMed...
  13. Curtis JJ. Hypertensinogenic mechanism of the calcineurin inhibitors. Curr Hypertens Rep 2002; 4: 377-380. Go to original source... Go to PubMed...
  14. Klein IHHT, Abrahams A, van Ede T, Hene RJ, Koomans HA., Ligtenberg G. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation 2002; 73(5): 732-736. Go to original source... Go to PubMed...
  15. Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev. 2010; (1): CD007893. Go to original source...
  16. Galiatsou E, Morris ST, Jardine AG, et al. Cardiac and vascular abnormalities in renal transplant patients: Differential effects of cyclosporin and azathioprine. J Nephrol 2000; 13(3): 185. Go to PubMed...
  17. Haydar AA, Covic A, Jayawardene S, et al. Insights from ambulatory blood pressure monitoring: diagnosis of hypertension and diurnal blood pressure in renal transplant recipients. Transplantation 2004; 77(6): 849-853. Go to original source... Go to PubMed...
  18. Kooman JP, Christiaans MH, Boots JM, et al. A comparison between office and ambulatory blood pressure measurements in renal transplant patients with chronic transplant nephropathy. Am J Kidney Dis 2001; 37(6): 1170. Go to original source... Go to PubMed...
  19. Jacobi J, Rockstroh J, John S, et al. Prospective analysis of the value of 24-hour ambulatory blood pressure on renal function after kidney transplantation. Transplantation 2000; 70(5): 819-827. Go to original source... Go to PubMed...
  20. Basić-Jukić N, Jurić I, Kes P, Bubić-Filipi L, Brunetta B, Pasini J. Arterial hypertension in renal transplant recipients. Acta Med Croatica 2007; 61(2): 171-176. Go to PubMed...
  21. Zhang R, Leslie B, Boudreaux JP, Frey D, Reisin E. Hypertension after kidney transplantation: impact, pathogenesis and therapy. Am J Med Sci. 2003; 325(4): 202-208. Go to original source... Go to PubMed...
  22. Kuypers DRJ, Neumayer HH, Fritsche L, Budde K, Rodicio JL, Vanrenterghem Y on behalf of the Lacidipine Study Group. Calcium Channel Blockade and Preservation of Renal Graft Function in Cyclosporine-Treated Recipients: A Prospective Randomized Placebo-Controlled 2-Year Study. Transplantation 2004; 78: 1204-1211. Go to original source... Go to PubMed...
  23. Halimi JM, Giraudeau B, Buchler M, et al. Enalapril/amlodipine combination in cyclosporine-treated renal transplant recipients: a prospective randomized trial. Clin Transplant 2007; 21(2): 277-284. Go to original source... Go to PubMed...
  24. Opie LH. Calcium channel antagonists. Part IV: Side effects and contraindications drug interactions and combinations. Cardiovasc Drugs Ther 1988; 2: 177-189. Go to original source... Go to PubMed...
  25. Fogari R. Ankle oedema and sympathetic activation. Drugs. 2005; 65(Suppl 2): 21-27. Go to original source... Go to PubMed...
  26. Richy FF, Laurent S. Efficacy and safety profiles of manidipine compared with amlodipine: A meta-analysis of headto-head trials. Blood Pressure 2011; 20: 54-59. Go to original source... Go to PubMed...
  27. de la Sierra A. Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotenzin system. J Hum Hypertens 2009; 23: 503-511. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.